SCHEMBL1348608

SCHEMBL1348608

O=C(O)c1ccc(-c2cccc(C3CN(S(=O)(=O)c4ccccc4)C(=O)N3c3ccccc3)c2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 2/20 0.43
CTSG P08311 2/20 0.42
CMA1 P23946 2/20 0.42
AKR1C3 P42330 2/20 0.39
AKR1C1 Q04828 2/20 0.39
PTGS2 P35354 2/20 0.38
PKM P14618 1/20 0.38
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
EGFR P00533 1/20 0.36
ALDH1A1 P00352 2/20 0.36
RAB9A P51151 1/20 0.36
TAS2R14 Q9NYV8 1/20 0.36
USP2 O75604 1/20 0.36
HPGD P15428 1/20 0.36
MAPK1 P28482 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HIF1A Q16665 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1348740 0.93 CMA1 (0.45) MCL1CTSGCMA1AKR1C3AKR1C1
SCHEMBL1347258 0.91 CTSG (0.46) MCL1CTSGCMA1PTGS2PKM
SCHEMBL1348640 0.90 CMA1 (0.44) MCL1CTSGCMA1AKR1C3AKR1C1
SCHEMBL15841773 0.87 BCL9 (0.37) MCL1AKR1C3AKR1C1PKMKMT2A
SCHEMBL1348651 0.85 FFAR1 (0.43) MCL1AKR1C3AKR1C1PKM
SCHEMBL1348509 0.85 PKM (0.37) MCL1CTSGCMA1AKR1C3AKR1C1
SCHEMBL1348981 0.84 NR1H2 (0.42) PTGS2PKMKMT2AALDH1A1RAB9A
SCHEMBL15841731 0.84 BCL9 (0.38) CTSGCMA1PKMKMT2AALDH1A1
SCHEMBL1348917 0.81 GRIA2 (0.43) PTGS2KMT2AALDH1A1RAB9AUSP2
SCHEMBL1459376 0.81 CMA1 (0.38) CTSGCMA1AKR1C3AKR1C1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2288594-B1 IMIDAZOLIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-07-02 EP claimed
US-8063088-B2 Imidazolidine derivatives HOFFMANN-LA ROCHE INC. (US) 2011-11-22 US claimed
EP-2288594-A1 IMIDAZOLIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-03-02 EP claimed
US-20090312382-A1 NOVEL IMIDAZOLIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-12-17 US claimed
WO-2009150109-A1 IMIDAZOLIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-12-17 WO claimed
EP-2288594-B1 IMIDAZOLIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-07-02 EP disclosed
US-8063088-B2 Imidazolidine derivatives HOFFMANN-LA ROCHE INC. (US) 2011-11-22 US disclosed
EP-2288594-A1 IMIDAZOLIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-03-02 EP disclosed
US-20090312382-A1 NOVEL IMIDAZOLIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-12-17 US disclosed
WO-2009150109-A1 IMIDAZOLIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312382-A1 NOVEL IMIDAZOLIDINE DERIVATIVES NR1H2, NR1H3, NR1D2 MCL1 1930/4885CTSG 4280/4885CMA1 4479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.